Table 2.

Immunosuppressive drug therapy after HTX

Administration of drug for >1 year	All patients (n=381)	Patients with malignancy (n=130)	Patients without malignancy (n=251)	P-value
	n/% of subgroup
Cyclosporine A	239/62.7%	92/70.8%	147/58.6%	0.0195*
Tacrolimus	149/39.1%	34/26.2%	115/45.8%	0.0002*
Azathioprine	152/39.9%	67/51.5%	85/33.9%	0.0008*
Mycophenolate mofetil	227/59.6%	59/45.4%	168/66.9%	<0.0001*
Steroids	207/54.3%	85/65.4%	122/48.6%	0.0018*
mTOR inhibitors	104/27.3%	19/14.6%	85/33.9%	<0.0001*

Note:

^*Statistically significant (P<0.05).

Abbreviations: HTX, heart transplantation; mTOR, mammalian target of rapamycin; n, number.